Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹8,569 Cr
up ₹217 Cr vs May 2025
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In June 2025 it disclosed 36 stocks worth ₹8,569 Cr, up ₹217 Cr from May 2025. Its largest positions were Sun Pharmaceutical Industries Limited (12.2%), Divi's Laboratories Limited (8.5%), Lupin Limited (6.1%); the ten largest together made up 57.4% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 75.4% of its equity. Cash and debt stood at 0.5%. Compared with May 2025 the fund entered 0 new stocks and exited 0.
Against 226 other Sectoral / Thematic funds
Concentration
77%
Top-10 weight is higher than 77% of peers
Breadth
31%
Holds more stocks than 31% of peers
Cash
7%
Holds more cash than 7% of peers
What these mean: concentration · cash
Holdings in June 2025
Download CSVEvery line the fund disclosed, with the change against May 2025. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 12.23% | down 0.33 pts | ₹1,048 Cr | down ₹1.2 Cr | Held |
| Divi's Laboratories Limited | 8.50% | down 0.99 pts | ₹729 Cr | down ₹64 Cr | Trimmed |
| Lupin Limited | 6.07% | up 0.25 pts | ₹520 Cr | up ₹33.9 Cr | Added |
| Cipla Limited | 5.62% | up 0.01 pts | ₹482 Cr | up ₹12.9 Cr | Added |
| Apollo Hospitals Enterprise Limited | 5.48% | up 0.14 pts | ₹470 Cr | up ₹23.5 Cr | Added |
| Dr. Reddy's Laboratories Limited | 5.18% | down 0.30 pts | ₹444 Cr | down ₹13.9 Cr | Trimmed |
| MedPlus Health Services Limited | 3.83% | down 0.37 pts | ₹328 Cr | down ₹22.5 Cr | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 3.63% | down 0.09 pts | ₹311 Cr | up ₹12 L | Held |
| Narayana Hrudayalaya Limited | 3.55% | up 0.61 pts | ₹304 Cr | up ₹58.9 Cr | Added |
| Vijaya Diagnostic Centre Limited | 3.32% | up 0.08 pts | ₹284 Cr | up ₹13.6 Cr | Added |
| Gland Pharma Limited | 3.27% | up 0.36 pts | ₹280 Cr | up ₹37.5 Cr | Added |
| Ajanta Pharma Limited | 2.88% | down <0.01 pts | ₹247 Cr | up ₹6.1 Cr | Added |
| Abbott India Limited | 2.86% | down 0.01 pts | ₹245 Cr | up ₹5.4 Cr | Added |
| Dr. Lal Path Labs Limited | 2.31% | down 0.05 pts | ₹198 Cr | up ₹69 L | Held |
| Zydus Lifesciences Limited | 2.31% | up 0.08 pts | ₹198 Cr | up ₹12 Cr | Added |
| Sai Life Sciences Limited | 2.31% | up 0.91 pts | ₹198 Cr | up ₹80.7 Cr | Added |
| Aurobindo Pharma Limited | 2.25% | down 0.09 pts | ₹193 Cr | down ₹2.2 Cr | Trimmed |
| Pfizer Limited | 2.11% | down 0.03 pts | ₹181 Cr | up ₹2 Cr | Added |
| Mankind Pharma Limited | 2.05% | down 0.19 pts | ₹176 Cr | down ₹11.2 Cr | Trimmed |
| Thyrocare Technologies Limited | 2.04% | down 0.18 pts | ₹175 Cr | down ₹10.4 Cr | Trimmed |
| JB Chemicals & Pharmaceuticals Limited | 1.96% | down 0.05 pts | ₹168 Cr | up ₹30 L | Held |
| Alkem Laboratories Limited | 1.87% | down 0.11 pts | ₹160 Cr | down ₹5.2 Cr | Trimmed |
| Sanofi India Limited | 1.71% | up <0.01 pts | ₹147 Cr | up ₹4.1 Cr | Added |
| Biocon Limited | 1.64% | up 0.72 pts | ₹141 Cr | up ₹63.9 Cr | Added |
| Sanofi Consumer Healthcare India Limited | 1.42% | up 0.07 pts | ₹122 Cr | up ₹9.1 Cr | Added |
| IPCA Laboratories Limited | 1.27% | down 0.07 pts | ₹109 Cr | down ₹2.7 Cr | Trimmed |
| Suraksha Diagnostic Limited | 1.24% | up 0.02 pts | ₹106 Cr | up ₹4.5 Cr | Added |
| Torrent Pharmaceuticals Limited | 1.21% | up 0.05 pts | ₹103 Cr | up ₹7.1 Cr | Added |
| Fortis Healthcare Limited | 1.02% | up 0.09 pts | ₹87.7 Cr | up ₹9.7 Cr | Added |
| Syngene International Limited | 0.95% | up 0.08 pts | ₹81.8 Cr | up ₹9.1 Cr | Added |
| Emcure Pharmaceuticals Limited | 0.71% | down 0.04 pts | ₹60.8 Cr | down ₹1.7 Cr | Trimmed |
| Indoco Remedies Limited | 0.68% | up 0.13 pts | ₹58.3 Cr | up ₹12.3 Cr | Added |
| AstraZeneca Pharma India Limited | 0.65% | up 0.04 pts | ₹55.7 Cr | up ₹4.7 Cr | Added |
| Akums Drugs and Pharmaceuticals Limited | 0.65% | up 0.08 pts | ₹55.3 Cr | up ₹7.7 Cr | Added |
| Cash, TREPS & receivables | 0.53% | down 0.89 pts | ₹45.8 Cr | down ₹73 Cr | Trimmed |
| Orchid Pharma Limited | 0.41% | up 0.04 pts | ₹35.2 Cr | up ₹4.2 Cr | Added |
| Concord Biotech Limited | 0.24% | up 0.01 pts | ₹20.6 Cr | up ₹1 Cr | Added |
What changed, May 2025 to Jun 2025
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Sai Life Sciences Limitedup ₹80.7 Cr (+0.91% pts)
- Biocon Limitedup ₹63.9 Cr (+0.72% pts)
- Narayana Hrudayalaya Limitedup ₹58.9 Cr (+0.61% pts)
- Gland Pharma Limitedup ₹37.5 Cr (+0.36% pts)
- Lupin Limitedup ₹33.9 Cr (+0.25% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since May 2025, the weight rose most in Healthcare Services (+0.6 pts) and Pharmaceuticals (+0.1 pts), and fell most in Retailing (−0.4 pts) and Pharmaceuticals & Biotechnology (−0.3 pts).
- Healthcare Services19.4% → 20.0%+0.6 pts
- Pharmaceuticals0.6% → 0.7%+0.1 pts
- Retailing4.3% → 3.8%−0.4 pts
- Pharmaceuticals & Biotechnology75.8% → 75.4%−0.3 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jun 2022 | Jun 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 80.3% | 78.7% | 76.8% | 77.1% | 75.8% | 75.4% |
| Healthcare Services | 17.4% | 17.6% | 19.1% | 18.9% | 19.4% | 20.0% |
| Retailing | — | 2.9% | 3.4% | 3.4% | 4.3% | 3.8% |
| Pharmaceuticals | 1.7% | 0.8% | 0.7% | 0.5% | 0.6% | 0.7% |
Allocation in Jun 2025change vs May 2025
- Pharmaceuticals & Biotechnology (26)75.4%▼ 0.3 pts
- Healthcare Services (8)20.0%▲ 0.6 pts
- Retailing (1)3.8%▼ 0.4 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Jun 2025
0.5%
▼ 0.9 pts vs May 2025
- Cash alone
- 0.6%
- cash and net receivables
- A year earlier
- 0.6%
- Jun 2024
- Last 12 months
- 0.3% – 4.4%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.